EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Optimizing the Antibiotic Potency and Metabolic Stability of Pyridomycin Using a Semisynthetic Approach

Katherine Valderrama, Oliver Horlacher, Gabriel Publicola, Patrick Eisenring, Maryline Kienle, Samira Boarbi, Mehdi Kiass, Jana Korduláková, Jonathan Chatagnon, Catherine Piveteau, Florence Leroux, Karin Savková und 10 weitere

Journal of Medicinal Chemistry · 12.02.2026 · 69 (3) · 2496-2508

DOI: 10.1021/acs.jmedchem.5c02409 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 27.01.2026. Verfasst von Katherine Valderrama und 21 weiteren Autor:innen. Beteiligte Einrichtung: Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur Lille, U1019 - UMR 9017 - CIIL - Center for Infection and Immunity of Lille, F-59000 Lille, Fr…. Hauptthemen laut MEDLINE: Tuberculosis, Pulmonary, Antitubercular Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Agence Nationale de la Recherche, Schweizerischer Nationalfonds zur F??rderung der Wissenschaftlichen Forschung, European Commission.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pyridomycin is a natural product with potent activity against Mycobacterium tuberculosis (Mtb), acting through direct inhibition of the fatty acid synthesis enzyme InhA. As a direct inhibitor, pyridomycin maintains activity on Mtb strains resistant to the InhA targeting prodrugs isoniazid and ethionamide. Evaluation of the drug-like properties of pyridomycin, however, found it to have poor in vitro metabolic stability, thus limiting its drug development potential. To address this limitation, semisynthetic derivatives were generated by replacing the metabolically labile hydroxypicolinic acid group with alternative (hetero)aromatic moieties, identifying several derivatives with improved in vitro metabolic stability and with comparable or even enhanced antibacterial activity. Pharmacokinetic studies in mice, however, revealed that these gains did not reduce systemic clearance in vivo, and neither pyridomycin nor its derivatives were effective in a murine pulmonary tuberculosis model. Overall, semisynthesis yielded more potent, P450-stable analogs, but the improvements were insufficient to provide measurable in vivo efficacy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Tuberculosis, PulmonaryAntitubercular AgentsHumansAnimalsMiceAnti-Bacterial AgentsMicrobial Sensitivity TestsOligopeptides

Substanzen

Anti-Bacterial AgentspyridomycinAntitubercular AgentsOligopeptides

Autor:innen und Institutionen

  • Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur Lille, U1019 - UMR 9017 - CIIL - Center for Infection and Immunity of Lille, F-59000 Lille, France.
  • Department of Chemistry and Applied Biosciences, Institute of Pharmaceutical Sciences, ETH Zürich, 8093 Zurich, Switzerland.
  • Univ. Toulouse, CNRS, IPBS, 31077 Toulouse, France.
  • Unit "Tuberculosis & Mycobacteria", Human Bacterial Diseases Service, Infectious Diseases in Humans, 1050 Brussels, Belgium.
  • Faculty of Natural Sciences, Department of Biochemistry, Comenius University in Bratislava, Ilkovičova 6, Mlynská dolina, 842 15 Bratislava, Slovakia.
  • Univ. Lille, Inserm, Institut Pasteur de Lille, U1177 - Drugs and Molecules for Living Systems, F-59000 Lille, France.

ORCID-Profile: Francois-Xavier Cantrelle, Lionel Mourey, Katarína Mikušová, Laurent Maveyraud, Karl-Heinz Altmann, Ruben C Hartkoorn

Förderung

  • Agence Nationale de la Recherche
  • Schweizerischer Nationalfonds zur F??rderung der Wissenschaftlichen Forschung
  • European Commission
  • Agent??ra na Podporu V??skumu a V??voja

Zitieren

APA

Valderrama, K., Horlacher, O., Publicola, G., Eisenring, P., Kienle, M., Boarbi, S., Kiass, M., Korduláková, J., Chatagnon, J., Piveteau, C., Leroux, F., Savková, K., Záhorszká, M., Cantrelle, F. X., Lherbet, C., Mourey, L., Mikušová, K., Mathys, V., Aichholz, R., …, & Hartkoorn, R. C. (2026). Optimizing the Antibiotic Potency and Metabolic Stability of Pyridomycin Using a Semisynthetic Approach. Journal of Medicinal Chemistry, 69(3), 2496-2508. https://doi.org/10.1021/acs.jmedchem.5c02409

Vancouver

Valderrama K, Horlacher O, Publicola G, Eisenring P, Kienle M, Boarbi S, et al. Optimizing the Antibiotic Potency and Metabolic Stability of Pyridomycin Using a Semisynthetic Approach. Journal of Medicinal Chemistry. 2026;69(3):2496-2508. doi:10.1021/acs.jmedchem.5c02409

BibTeX
@article{Valderrama2026,
  author = {Valderrama, Katherine and Horlacher, Oliver and Publicola, Gabriel and Eisenring, Patrick and Kienle, Maryline and Boarbi, Samira and Kiass, Mehdi and Korduláková, Jana and Chatagnon, Jonathan and Piveteau, Catherine and Leroux, Florence and Savková, Karin and Záhorszká, Monika and Cantrelle, Francois-Xavier and Lherbet, Christian and Mourey, Lionel and Mikušová, Katarína and Mathys, Vanessa and Aichholz, Reiner and Maveyraud, Laurent and Altmann, Karl-Heinz and Hartkoorn, Ruben C},
  title = {Optimizing the Antibiotic Potency and Metabolic Stability of Pyridomycin Using a Semisynthetic Approach},
  journal = {Journal of Medicinal Chemistry},
  year = {2026},
  volume = {69},
  number = {3},
  pages = {2496--2508},
  doi = {10.1021/acs.jmedchem.5c02409}
}
Kostenlos starten →